Breaking Monopolies and Setting Benchmarks: Core Medical's Corheart® 6 Joins Global Elite in Artificial Heart Market

Recently, Shenzhen Core Medical Technology Co., Ltd. (hereinafter referred to as "Core Medical") announced that the Corheart® 6 Implantable Left Ventricular Assist System successfully completed its 1000th clinical implantation. This product will become the second globally and the first in China to reach this milestone among third-generation fully magnetically levitated artificial hearts, following Abbott's HeartMate 3. The breakthrough of over a thousand implants marks that China has not only successfully broken the long-term technological monopoly in the artificial heart field but also demonstrated that Chinese innovative enterprises are solidifying their leading position in the global top tier with a complete industrial layout.

Artificial heart, as one of the ultimate means for treating end-stage heart failure, has extremely high technical barriers, and its global market was long monopolized by international giants. The technology has evolved through three generations: from the initial pulsatile pump, to the second-generation axial flow pump, to the currently most advanced third-generation fully magnetically levitated centrifugal pump. Each iteration focuses on better blood compatibility, lower complication rates, and smaller pump size. Among these, miniaturization, lightweight design, and high blood compatibility have become the core directions pursued by both technology and clinical practice.

Core Medical has broken the monopoly, thanks to its pioneering proposal of "time-sharing and zoning dynamic axial full magnetic suspension control technology," which has been successfully applied in the field of artificial hearts. The innovation of this underlying technology has enabled the "Chinese heart" to stand shoulder-to-shoulder with world-leading products.

Based on this technology, Corheart® 6 has achieved significant advantages in miniaturization and integration, completing a systematic optimization closed loop of "performance-clinical-experience". This allows Corheart® 6 to provide a large flow support of 10L/min while being 40% lighter and 30% smaller in volume than mainstream international products, reaching an internationally leading level in blood compatibility and power consumption control.

This technological advantage has directly translated into significant clinical benefits. The smaller implant volume allows for a smaller surgical incision, which not only reduces surgical trauma for patients but also speeds up postoperative recovery. At the same time, the ingenious magnetic levitation design and optimized blood flow field effectively reduce the risk of thrombosis caused by heat accumulation in the blood pump, enhancing the long-term safety of the product.

The outstanding performance of the product has been fully validated by authoritative data. According to the evaluation materials from the National Medical Products Administration (NMPA), "Corheart® 6 has a simpler structure, lighter weight, smaller size, and lower power consumption. In clinical applications, the surgical incision is smaller, patient recovery is faster, the applicable population is broader, and it can reduce the risk of thrombosis caused by blood pump heat." Additionally, at the 2025 Tongji International Cardiovascular Conference and the Chinese Biomedical Engineering Conference, data released by Fuwai Hospital, Chinese Academy of Medical Sciences, showed that Corheart® 6 captured 46% of the domestic market share in its first year on the market, and in 2025 it exceeded 50%, firmly ranking first in China's artificial heart field.

It is worth mentioning that the miniaturization technology of Corheart® 6 has successfully broken through the "adult-child" compatibility barrier. To date, this product has successfully completed implants in more than 30 pediatric heart failure patients, demonstrating wide clinical applicability and offering new hope for children with heart failure worldwide.

From Technical Breakthrough to Industry Benchmark: The Thousandth Implant of Corheart® 6 Represents a Model Case of Independent Innovation and Commercial Implementation in China's High-End Medical Equipment Industry, Marking a Historic Leap for "Made in China" from "Catching Up" to "Running Alongside" and Even "Leading" in Some Areas on the Global Map of High-End Medical Equipment.